BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐rearranged NSCLC: a Case Report

Corresponding Author

Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Corresponding Author: Wenxiu Yao, M.D., Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, 610041, China; Email: ywxhlx@sina.comSearch for more papers by this author

留言 (0)

沒有登入
gif